Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial
Modern Rheumatology · 2025
DOI: 10.1093/mr/roae111 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Yoshiya Tanaka und 13 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To describe the efficacy of anifrolumab versus placebo in Japanese systemic lupus erythematosus (SLE) patients with low complement (C3 or C4) and/or who are positive for anti-double stranded DNA antibodies.
Methods
This was a descriptive post hoc analysis of Japanese SLE patients with serological manifestations in the Treatment of Uncontrolled Lupus via the Interferon Pathway-2 (TULIP-2) trial who received either anifrolumab or placebo.
Results
Of the 43 patients enrolled, 79.2% (19/24) and 73.7% (14/19) had low C3, low C4, and/or were positive for anti-double stranded DNA antibodies at baseline in the anifrolumab and placebo groups, respectively. At Week 52, 52.6% (10/19) and 7.1% (1/14) patients in the anifrolumab and placebo groups, respectively, achieved a British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response. The proportion of patients who tapered their glucocorticoid (GC) dose throughout the study, without increasing their dose, or who sustained baseline GC doses of ≤7.5 mg/day was numerically higher in the anifrolumab group [78.9% (15/19)] than in the placebo group [50.0% (7/14)].
Conclusions
In line with the clinical profile of anifrolumab in the TULIP-2 study, the efficacy of anifrolumab was shown in Japanese SLE patients with serological manifestations achieving a BICLA response, and with tapered GC dose or sustained GC doses of ≤7.5 mg/day.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
- Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan.
- Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
- Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.
- Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan.
ORCID-Profile: Yoshiya Tanaka
Zitieren
APA
Tanaka, Y., Atsumi, T., Okada, M., Miyamura, T., Ishii, T., Nishiyama, S., Matsumura, R., Hayashi, N., Matsumoto, T., Yabe-Wada, T., Yamaguchi, Y., Abreu, G., Lindholm, C., & Takeuchi, T. (2025). Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial. Modern Rheumatology. https://doi.org/10.1093/mr/roae111
Vancouver
Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, et al. Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial. Modern Rheumatology. 2025. doi:10.1093/mr/roae111
BibTeX
@article{Tanaka2025,
author = {Tanaka, Yoshiya and Atsumi, Tatsuya and Okada, Masato and Miyamura, Tomoya and Ishii, Tomonori and Nishiyama, Susumu and Matsumura, Ryutaro and Hayashi, Nobuya and Matsumoto, Takahiro and Yabe-Wada, Toshiki and Yamaguchi, Yoshiyuki and Abreu, Gabriel and Lindholm, Catharina and Takeuchi, Tsutomu},
title = {Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roae111}
}
EUVIMED